MKI67 and breast carcinoma: Taking into account the immunohistochemical characteristics, breast cancer patients with low Ki67 expression (<20%) showed higher Δ%T0-T1 of resolvin D2 compared to those with high Ki67 expression (≥20%) (Figure 5) (p = 0.046).